Get started
Author

Chengying Xie

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity in vitro and in vivo
2011 · Shu Tian, Haitian Quan, et al. · Cancer Science · 513
PDF
Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor
2018 · Chengying Xie, Xiaozhe Wan, et al. · Cancer Science · 349
PDF
Pharmacologic characterization of fluzoparib, a novel poly( ADP ‐ribose) polymerase inhibitor undergoing clinical trials
2019 · Lei Wang, Changyong Yang, et al. · Cancer Science · 98
PDF
High MRI performance fluorescent mesoporous silica-coated magnetic nanoparticles for tracking neural progenitor cells in an ischemic mouse model
2013 · Lu Zhang, Yao Wang, et al. · Nanoscale · 84
In vivo flow cytometry reveals a circadian rhythm of circulating tumor cells
2021 · Xi Zhu, Yuanzhen Suo, et al. · Light Science & Applications · 83
PDF
Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models
2019 · Fei Long, Ye He, et al. · Cancer Science · 83
PDF
Systemically Infused Mesenchymal Stem Cells Show Different Homing Profiles in Healthy and Tumor Mouse Models
2017 · Chengying Xie, Zhangru Yang, et al. · Stem Cells Translational Medicine · 81
PDF
Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species
2018 · Chen-chun Zhong, Feng Chen, et al. · Acta Pharmacologica Sinica · 67
PDF
Proportion of circulating tumor cell clusters increases during cancer metastasis
2016 · Yuanzhen Suo, Chengying Xie, et al. · Cytometry Part A · 61
PDF
Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist
2018 · Chengying Xie, Huajun Zhao, et al. · Journal of Cellular and Molecular Medicine · 60
PDF
RON confers lapatinib resistance in HER2-positive breast cancer cells
2013 · Quanren Wang, Haitian Quan, et al. · Cancer Letters · 57
Dysoxylactam A: A Macrocyclolipopeptide Reverses P-Glycoprotein-Mediated Multidrug Resistance in Cancer Cells
2019 · Cui-Ping Liu, Cheng-Ying Xie, et al. · Journal of the American Chemical Society · 52
DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction
2018 · Xiangling Chen, Peng Liu, et al. · Cancer Letters · 52
NL ‐103, a novel dual‐targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations
2014 · Jie Zhao, Haitian Quan, et al. · Pharmacology Research & Perspectives · 36
PDF
Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer
2012 · Cheng-Ying Xie, Yong-Ping Xu, et al. · Anti-Cancer Drugs · 36
Monitoring circulating prostate cancer cells by in vivo flow cytometry assesses androgen deprivation therapy on metastasis
2018 · Kai Pang, Chengying Xie, et al. · Cytometry Part A · 32
PDF
HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance
2010 · H Luo, H Quan, et al. · Leukemia · 32
Design and Synthesis of Triazole-Containing HDAC Inhibitors That Induce Antitumor Effects and Immune Response
2023 · Nan Sun, Kexin Yang, et al. · Journal of Medicinal Chemistry · 30
Near infrared in vivo flow cytometry for tracking fluorescent circulating cells
2015 · Yuanzhen Suo, Tao Liu, et al. · Cytometry Part A · 30
PDF
Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A2A Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents
2021 · Wenzhong Yan, Lijun Ling, et al. · Journal of Medicinal Chemistry · 29
Phosphodiesterase 3/4 Inhibitor Zardaverine Exhibits Potent and Selective Antitumor Activity against Hepatocellular Carcinoma Both In Vitro and In Vivo Independently of Phosphodiesterase Inhibition
2014 · Liping Sun, Haitian Quan, et al. · PLoS ONE · 29
PDF
Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo
2024 · Dazhao Mi, Cheng Li, et al. · European Journal of Medicinal Chemistry · 28
Puquitinib, a novel orally available PI 3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia
2017 · Chengying Xie, Ye He, et al. · Cancer Science · 27
PDF
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling
2023 · Yafang Wang, Mingyue Yao, et al. · Experimental Hematology and Oncology · 26
PDF
Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma
2018 · Ming-zhao Gao, Hong-bin Wang, et al. · Acta Pharmacologica Sinica · 26
PDF
Works count: 84
Citation count: 2,347
H-index: 25
I10-index: 41
Year
Topic
Type